Synthesis and biological evaluation of N-(3-fluorobenzyl)-4-(1-(methyl-d3)-1H-indazol-5-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-amine as a novel, potent ALK5 receptor inhibitor
作者:Byung-Nam Kang、Hong-Jun Kang、Sunjoo Kim、Jungwoo Lee、Jinwoo Lee、Hee-Jin Jeong、Seeun Jeon、Youngdo Shin、Cheolhwan Yoon、Cheolkyu Han、Jeongbeob Seo、Jaesook Yun
DOI:10.1016/j.bmcl.2023.129205
日期:2023.4
Specific inhibition of ALK5 provides a novel method for controlling the development of cancers and fibrotic diseases. In this work, a novel series of N-(3-fluorobenzyl)-4-(1-(methyl-d3)-1H-indazol-5-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-amine (11), a potential clinical candidate, was synthesized by strategic incorporation of deuterium at potential metabolic soft spots and identified as ALK5 inhibitors
特异性抑制 ALK5 为控制癌症和纤维化疾病的发展提供了一种新方法。在这项工作中,一系列新的N -(3-fluorobenzyl)-4-(1-(methyl-d 3 )-1 H -indazol-5-yl)-5-(6-methylpyridin-2-yl)- 1 H -imidazol-2-amine ( 11 ) 是一种潜在的临床候选药物,通过在潜在代谢软点处战略性掺入氘合成,并被鉴定为 ALK5 抑制剂。该化合物作为 CYP450 抑制剂 (IC 50 = >10 μM) 对 CYP 介导的药物-药物相互作用具有低潜力,并在细胞测定中显示出有效的抑制作用 (IC 50 = 3.5 ± 0.4 nM)。11的药代动力学评价在小鼠中表现出适度的清除率 (29.0 mL/min/kg),并且在小鼠中还显示出高口服生物利用度 ( F = 67.6%)。